SUN / TRY

SUN / USDT

TWT / TRY

TWT / USDT

W / FDUSD

W / TRY

W / USDC

W / USDT

BROCCOLI714 / USDT

BROCCOLI714 / USDC

SPK / FDUSD

PROM / USDT

PEOPLE / BTC

DOLO / USDT

DOLO / TRY

DOLO / FDUSD

DOLO / BNB

FLM / BTC

TUT / USDC

MITO / USDT

SHARP CHUCKS N MACHINES L

TVS ELECTRONICS LTD

INTENSE TECHNOLOGIES LTD

STL NETWORKS LIMITED

DEEPAK BUILDERS & ENG I L

SHALIM PAINTS LTD

GTL LTD

NATURAL CAPSULES LIMITED

POONAWALLA FINCORP LTD

ASHOKA METCAST LIMITED

ZYDUS WELLNESS LIMITED

SUNDARAM FINANCE HOLD LTD

NAGREEKA EXPORTS LTD.

QUICKTOUCH TECHNOLOGIES L

XPRO INDIA LIMITED

ONYX BIOTEC LIMITED

BRAND CONCEPTS LIMITED

RUSHIL DECOR LIMITED

YATRA ONLINE LIMITED

SURANI STEEL TUBES LTD.

Click here to get full coverage on Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases  Yahoo Finance

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Click here to get full coverage on Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ  Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Click here to get full coverage on Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites  Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Click here to get full coverage on Biocon arm's retinal disorder medication Yesafili gets public funding in Canada - CNBC TV18

Biocon arm's retinal disorder medication Yesafili gets public funding in Canada  CNBC TV18

Biocon arm's retinal disorder medication Yesafili gets public funding in Canada - CNBC TV18

Click here to get full coverage on Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs - The Economic Times

Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs  The Economic Times

Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs - The Economic Times

Click here to get full coverage on Trading Radar For September 18: Biocon, Indosolar, Yes Bank, Cochin Shipyard, Dixon, Hyundai Stocks Are On Investors’ Watchlist - MSN

Trading Radar For September 18: Biocon, Indosolar, Yes Bank, Cochin Shipyard, Dixon, Hyundai Stocks Are On Investors’ Watchlist  MSN

Trading Radar For September 18: Biocon, Indosolar, Yes Bank, Cochin Shipyard, Dixon, Hyundai Stocks Are On Investors’ Watchlist - MSN

Click here to get full coverage on Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - PR Newswire

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars  PR Newswire

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - PR Newswire

Click here to get full coverage on Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars to treat osteoporosis and bone... - Moneycontrol

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars to treat osteoporosis and bone...  Moneycontrol

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars to treat osteoporosis and bone... - Moneycontrol

Click here to get full coverage on Biocon Rises 2% as US FDA Approves Denosumab Biosimilars - HDFC Sky

Biocon Rises 2% as US FDA Approves Denosumab Biosimilars  HDFC Sky

Biocon Rises 2% as US FDA Approves Denosumab Biosimilars - HDFC Sky

Click here to get full coverage on Biocon gains after arm gets USFDA nod for two denosumab biosimilars - Business Standard

Biocon gains after arm gets USFDA nod for two denosumab biosimilars  Business Standard

Biocon gains after arm gets USFDA nod for two denosumab biosimilars - Business Standard

Click here to get full coverage on Biocon Shares Gain 3% on Gaining Two USFDA Approvals - Equitypandit

Biocon Shares Gain 3% on Gaining Two USFDA Approvals  Equitypandit

Biocon Shares Gain 3% on Gaining Two USFDA Approvals - Equitypandit

Click here to get full coverage on Biocon eyes generic semaglutide market for 2026 - Endpoints News

Biocon eyes generic semaglutide market for 2026  Endpoints News

Biocon eyes generic semaglutide market for 2026 - Endpoints News

Click here to get full coverage on Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States  PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Click here to get full coverage on Gainers & Losers: Poonawalla Fincorp, Dev Accelerator, and Biocon among 7 major movers on Thursday. Here’s why - The Economic Times

Gainers & Losers: Poonawalla Fincorp, Dev Accelerator, and Biocon among 7 major movers on Thursday. Here’s why  The Economic Times

Gainers & Losers: Poonawalla Fincorp, Dev Accelerator, and Biocon among 7 major movers on Thursday. Here’s why - The Economic Times

Click here to get full coverage on Biocon share price rises 3% as arm gets USFDA nod for two drugs; details - Business Standard

Biocon share price rises 3% as arm gets USFDA nod for two drugs; details  Business Standard

Biocon share price rises 3% as arm gets USFDA nod for two drugs; details - Business Standard

Click here to get full coverage on Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives  PR Newswire

Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives - PR Newswire

Click here to get full coverage on Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says  Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Click here to get full coverage on Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.  PR Newswire

Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. - PR Newswire

Click here to get full coverage on Biocon Biologics receives U.S. Food and Drug Administration approval for Bosaya and Aukelso, Denosumab biosimilars - MarketScreener

Biocon Biologics receives U.S. Food and Drug Administration approval for Bosaya and Aukelso, Denosumab biosimilars  MarketScreener

Biocon Biologics receives U.S. Food and Drug Administration approval for Bosaya and Aukelso, Denosumab biosimilars - MarketScreener

Click here to get full coverage on Biocon Biologics gets US FDA nod for two drugs to treat osteoporosis, bone loss - CNBC TV18

Biocon Biologics gets US FDA nod for two drugs to treat osteoporosis, bone loss  CNBC TV18

Biocon Biologics gets US FDA nod for two drugs to treat osteoporosis, bone loss - CNBC TV18

Click here to get full coverage on Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars - Business Standard

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars  Business Standard

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars - Business Standard

Click here to get full coverage on Biocon shares rise 1.65% amid high volume - Moneycontrol

Biocon shares rise 1.65% amid high volume  Moneycontrol

Biocon shares rise 1.65% amid high volume - Moneycontrol

Click here to get full coverage on Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States  GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Click here to get full coverage on Biocon arm gets Ontario listing for retinal drug; check details - Upstox

Biocon arm gets Ontario listing for retinal drug; check details  Upstox

Biocon arm gets Ontario listing for retinal drug; check details - Upstox

Click here to get full coverage on Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea  Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Click here to get full coverage on Biocon CEO reveals plans for generic Ozempic launch in key markets - CNBC TV18

Biocon CEO reveals plans for generic Ozempic launch in key markets  CNBC TV18

Biocon CEO reveals plans for generic Ozempic launch in key markets - CNBC TV18

Click here to get full coverage on Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion - Medical Dialogues

Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion  Medical Dialogues

Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion - Medical Dialogues

Click here to get full coverage on Stocks to Watch today: YES Bank, Indosolar, Cochin Ship, Biocon, Havells - Business Standard

Stocks to Watch today: YES Bank, Indosolar, Cochin Ship, Biocon, Havells  Business Standard

Stocks to Watch today: YES Bank, Indosolar, Cochin Ship, Biocon, Havells - Business Standard

Click here to get full coverage on Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% - Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%  Biocon

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15% - Biocon

Click here to get full coverage on Stocks in news: ZEE, Apollo Tyres, Airfloa Rail Technology, LTIMindtree, Biocon - The Economic Times

Stocks in news: ZEE, Apollo Tyres, Airfloa Rail Technology, LTIMindtree, Biocon  The Economic Times

Stocks in news: ZEE, Apollo Tyres, Airfloa Rail Technology, LTIMindtree, Biocon - The Economic Times

Click here to get full coverage on Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis - PR Newswire

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis  PR Newswire

Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis - PR Newswire

Click here to get full coverage on Biocon Foundation Begins Construction of New School Building in Kodamballi to Support 250 Students - TheCSRUniverse

Biocon Foundation Begins Construction of New School Building in Kodamballi to Support 250 Students  TheCSRUniverse

Biocon Foundation Begins Construction of New School Building in Kodamballi to Support 250 Students - TheCSRUniverse

Click here to get full coverage on Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection - CNBC TV18

Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection  CNBC TV18

Biocon Biologics’ Bengaluru facility gets five observations from US FDA inspection - CNBC TV18

Click here to get full coverage on Biocon inaugurates first US manufacturing facility in New Jersey - Medical Dialogues

Biocon inaugurates first US manufacturing facility in New Jersey  Medical Dialogues

Biocon inaugurates first US manufacturing facility in New Jersey - Medical Dialogues

Click here to get full coverage on Top stocks in news: Cohance, Indosolar, Dixon Tech, Federal Bank, Cochin Shipyard, Biocon - MSN

Top stocks in news: Cohance, Indosolar, Dixon Tech, Federal Bank, Cochin Shipyard, Biocon  MSN

Top stocks in news: Cohance, Indosolar, Dixon Tech, Federal Bank, Cochin Shipyard, Biocon - MSN

Click here to get full coverage on Pharma index snaps four-day rally as Dr Reddy's, Biocon, other shares slide up to 2 percent: Factors at... - Moneycontrol

Pharma index snaps four-day rally as Dr Reddy's, Biocon, other shares slide up to 2 percent: Factors at...  Moneycontrol

Pharma index snaps four-day rally as Dr Reddy's, Biocon, other shares slide up to 2 percent: Factors at... - Moneycontrol

Click here to get full coverage on Half of the habitat of Australia's highly imperilled narrow-range species is outside protected areas - ScienceDirect.com

Half of the habitat of Australia's highly imperilled narrow-range species is outside protected areas  ScienceDirect.com

Half of the habitat of Australia's highly imperilled narrow-range species is outside protected areas - ScienceDirect.com

Click here to get full coverage on U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab) - PR Newswire

U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab)  PR Newswire

U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab) - PR Newswire

Click here to get full coverage on "Emergency Measures Needed": India Inc Flags Bengaluru Civic Issues - NDTV

"Emergency Measures Needed": India Inc Flags Bengaluru Civic Issues  NDTV

"Emergency Measures Needed": India Inc Flags Bengaluru Civic Issues - NDTV

Click here to get full coverage on Stocks to Watch Today: Cohance Lifesciences, Indosolar, Biocon, Cochin Shipyard, Dixon Technologies,... - Moneycontrol

Stocks to Watch Today: Cohance Lifesciences, Indosolar, Biocon, Cochin Shipyard, Dixon Technologies,...  Moneycontrol

Stocks to Watch Today: Cohance Lifesciences, Indosolar, Biocon, Cochin Shipyard, Dixon Technologies,... - Moneycontrol

Click here to get full coverage on Biocon's Q3 revenue dips; banks on obesity drugs for future growth - Reuters

Biocon's Q3 revenue dips; banks on obesity drugs for future growth  Reuters

Biocon's Q3 revenue dips; banks on obesity drugs for future growth - Reuters

Click here to get full coverage on AB Capital, Biocon among top gainers on Nifty Midcap 150 - Moneycontrol

AB Capital, Biocon among top gainers on Nifty Midcap 150  Moneycontrol

AB Capital, Biocon among top gainers on Nifty Midcap 150 - Moneycontrol

Click here to get full coverage on Biocon opens first US manufacturing facility: Kiran Mazumdar-Shaw confirms FDA approval — Here's all we know - Mint

Biocon opens first US manufacturing facility: Kiran Mazumdar-Shaw confirms FDA approval — Here's all we know  Mint

Biocon opens first US manufacturing facility: Kiran Mazumdar-Shaw confirms FDA approval — Here's all we know - Mint

Click here to get full coverage on Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%  Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon

Click here to get full coverage on Stock Alert: Biocon, Cochin Shipyard, Muthoot Microfin, Lodha Developers - Business Standard

Stock Alert: Biocon, Cochin Shipyard, Muthoot Microfin, Lodha Developers  Business Standard

Stock Alert: Biocon, Cochin Shipyard, Muthoot Microfin, Lodha Developers - Business Standard

Click here to get full coverage on Profit margins, US medicine supplies may get hit: Biocon - The Times of India

Profit margins, US medicine supplies may get hit: Biocon  The Times of India

Profit margins, US medicine supplies may get hit: Biocon - The Times of India

Click here to get full coverage on Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe - insights.citeline.com

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe  insights.citeline.com

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe - insights.citeline.com

Click here to get full coverage on After a $3.3 bn acquisition, is it finally time to look at Biocon? - The Indian Express

After a $3.3 bn acquisition, is it finally time to look at Biocon?  The Indian Express

After a $3.3 bn acquisition, is it finally time to look at Biocon? - The Indian Express

Click here to get full coverage on Watch Biocon Executive Chairperson on Insulin Capacity - Bloomberg.com

Watch Biocon Executive Chairperson on Insulin Capacity  Bloomberg.com

Watch Biocon Executive Chairperson on Insulin Capacity - Bloomberg.com

Click here to get full coverage on Biocon inaugurates first manufacturing facility in US - The Economic Times

Biocon inaugurates first manufacturing facility in US  The Economic Times

Biocon inaugurates first manufacturing facility in US - The Economic Times

Click here to get full coverage on Why Biocon is expanding in the US with a $30 million generics plant - Business Today

Why Biocon is expanding in the US with a $30 million generics plant  Business Today

Why Biocon is expanding in the US with a $30 million generics plant - Business Today

Click here to get full coverage on Stocks in Focus: Biocon, Cochin Shipyard, Yes Bank, and Others - Equitypandit

Stocks in Focus: Biocon, Cochin Shipyard, Yes Bank, and Others  Equitypandit

Stocks in Focus: Biocon, Cochin Shipyard, Yes Bank, and Others - Equitypandit

Click here to get full coverage on Biocon expands US footprint with new Cranbury manufacturing facility - Business Standard

Biocon expands US footprint with new Cranbury manufacturing facility  Business Standard

Biocon expands US footprint with new Cranbury manufacturing facility - Business Standard

Click here to get full coverage on Biocon Pharma bags tentative USFDA nod for diabetes medicine Sitagliptin - Medical Dialogues

Biocon Pharma bags tentative USFDA nod for diabetes medicine Sitagliptin  Medical Dialogues

Biocon Limited (BIOCON)

Price Chart

Key Statistics

Technicals

About BIOCON

Latest News

Biocon Biologics' Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases - Yahoo Finance

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Advanced Charts

Top Gainers

Top Losers